- The disease
- Breast cancer is the most commonly diagnosed cancer in women globally. Detecting it at an early stage is associated with a wider range of treatment options and better patient outcomes, as documented in population screening literature. Current standard detection relies primarily on mammography, which has known limitations including false positives and variable sensitivity across tissue densities (per BreastScreen Australia programme documentation). A complementary blood-based test could be used alongside mammography to assist clinicians in identifying patients who warrant further investigation.
- What the asset is trying to do
- BCALMarker is a blood test designed to detect calcium-binding proteins as biomarkers associated with early breast cancer. The test is intended to be used as an adjunct to mammography, not as a standalone replacement for imaging. The specific calcium-binding protein targets and the analytical platform used to quantify them are . As of May 2026, BCAL has signed a validation agreement with Sonic USA for a product referred to as Breastest V2 (per ASX announcement, 27 May 2026).
- What the trial is measuring, and why it matters
- Formal clinical validation study design, primary endpoints, and registered trial identifiers are . A validation agreement with Sonic USA announced on 27 May 2026 (per ASX announcement) indicates that analytical and clinical validation work is under way, but the specific metrics being assessed and the protocol have not been disclosed in the input data provided. Typical endpoints for a diagnostic validation study in this setting include sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) relative to a reference standard.
- Efficacy benchmarks in this setting
- For context on the approved screening landscape, mammography remains the standard tool recommended in population-based programmes; BreastScreen Australia reports a sensitivity of approximately 75% for screen-detected cancers in its programme (per AIHW Breast Cancer in Australia report). Circulating tumour DNA (ctDNA) multi-cancer early detection assays such as Galleri (Illumina/GRAIL) have reported sensitivity for breast cancer of approximately 24% at high specificity in the PATHFINDER study (Klein et al, Nature 2021), illustrating the difficulty of blood-based early detection in this setting. Any early-stage figures from BCALMarker studies are not statistically comparable to these established benchmarks given differences in study design, population, and stage of development.
- Commercial context
- No blood-based early detection test for breast cancer has received regulatory approval in Australia or the United States as of the date of the input data. BCAL also disclosed on 30 March 2026 that it has submitted a Medical Services Advisory Committee (MSAC) application in Australia for a separate product, Avantect, focused on pancreatic cancer early detection (per ASX announcement, 30 March 2026). The company appears to be developing a broader early detection cancer platform, as indicated by the 19 May 2026 announcement of an 'Early Detection Cancer Platform' launch (per ASX announcement). Financial terms of the Sonic USA validation agreement have not been disclosed. Whether BCALMarker is the company's lead asset relative to its pancreatic programme is .